Review
doi: 10.1111/j.1365-2249.1997.tb08310.x.
Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation
Affiliations
- PMID: 9367395
- PMCID: PMC2265499
- DOI: 10.1111/j.1365-2249.1997.tb08310.x
Item in Clipboard
Review
Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation
Clin Exp Immunol.
1997 Nov.
No abstract available
Similar articles
-
Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone.Immunol Lett. 1999 Jun 1;68(2-3):325-32. doi: 10.1016/s0165-2478(99)00055-3. Immunol Lett. 1999. PMID: 10424439
-
Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.Clin Immunol Immunopathol. 1996 Dec;81(3):219-23. doi: 10.1006/clin.1996.0181. Clin Immunol Immunopathol. 1996. PMID: 8938097 Review. No abstract available.
-
Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester.J Immunol. 2002 Mar 15;168(6):2644-51. doi: 10.4049/jimmunol.168.6.2644. J Immunol. 2002. PMID: 11884428
-
Thalidomide analogs from diamines: Synthesis and evaluation as inhibitors of TNF-alpha production.Chem Pharm Bull (Tokyo). 2007 Feb;55(2):223-6. doi: 10.1248/cpb.55.223. Chem Pharm Bull (Tokyo). 2007. PMID: 17268092
-
Novel biological response modifiers derived from thalidomide.Curr Med Chem. 1998 Jun;5(3):163-78. Curr Med Chem. 1998. PMID: 9562600 Review.
Cited by
-
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro.Clin Exp Immunol. 2000 Sep;121(3):472-9. doi: 10.1046/j.1365-2249.2000.01332.x. Clin Exp Immunol. 2000. PMID: 10971513 Free PMC article.
-
Transport of thalidomide by the human intestinal caco-2 monolayers.Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):49-61. doi: 10.1007/BF03226408. Eur J Drug Metab Pharmacokinet. 2005. PMID: 16010862
-
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.Clin Rheumatol. 2016 Jun;35(6):1521-7. doi: 10.1007/s10067-016-3256-3. Epub 2016 Apr 21. Clin Rheumatol. 2016. PMID: 27097914
-
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23. Xenobiotica. 2011. PMID: 21859393 Free PMC article. Clinical Trial.
-
The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.J Palliat Med. 2012 Oct;15(10):1059-64. doi: 10.1089/jpm.2012.0146. Epub 2012 Aug 10. J Palliat Med. 2012. PMID: 22880820 Free PMC article. Clinical Trial.
References
-
- Hennies H-H, Günzler WA, Flohé L. Influence of supidimide on brain neurotransmitter systems of rats and mice. Arzneimittelforschugh. 1984;34:1471–80. - PubMed
-
- Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303. - PubMed
-
- Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:408–14. - PubMed
-
- Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol. 996(81):219–23. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
